1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Diagnostics & Research
HTG Molecular Diagnostics, Inc.

HTG Molecular Diagnostics, Inc.

HTGMQ
HTG Molecular Diagnostics, Inc.US flagOther OTC
0.00
USD
- -
- -
221.00Market Cap
HTG Molecular Diagnostics, Inc.
HTGMQ
(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
TTM
FRC
1,339.55
1,211.16
1,797.49
161.01
129.89
250.7
140.63
90.73
22.17
15.41
7.16
4.6
Revenue per Share
-7,652.74
-7,580.91
-9,288.87
-898.88
-658.95
-322.04
-107.61
-91.17
-54.12
-29.66
-24.28
-14.92
Basic EPS, GAAP
-4,724.05
-6,803.95
-7,480.72
-819.91
-611.91
-298.82
-92.37
-84.09
-43.42
-29.68
-20.73
-12.48
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-22,910.7
-29,271.17
-36,807.98
-3,567.83
-2,925.28
-2,285.43
-987.47
-804.64
-495.73
-360.43
-258.55
-173.99
Book Value per Share
-23,840.59
-31,453.52
-37,618.75
672.99
-141.53
-51.97
137.94
113.24
37.56
17.99
6.06
0.35
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
1
1
Basic Weighted Avg Shares
2
2
3
4
5
15
22
19
9
9
6
6
Sales/Revenue/Turnover
-425.21
-531.21
-385.97
-467.39
-474.04
-120.08
-75.15
-98.73
-229.1
-200.11
-327.19
-315.21
Operating Margin (%)
- -
- -
- -
1
1
1
1
1
1
1
1
- -
Depreciation Expense
-13
-12
-14
-21
-26
-19
-16
-19
-21
-17
-22
-20
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-514.91
-524.7
-419.3
-529.44
-507.32
-128.46
-76.52
-100.49
-244.13
-192.49
-339.2
-324.28
Profit Margin (%)
6
1
3
29
5
5
31
32
26
17
7
3
Working Capital
- -
- -
10
8
5
3
10
8
9
6
1
- -
LT Debt
-18
-22
-24
17
-6
-3
21
24
14
10
5
- -
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'22
Dec'22
Mar'23
ST Debt
4
4
4
LT Borrowings
1
- -
- -
LT Finance Leases
1
1
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1
2
2
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Sep'22
Dec'22
Mar'23
Total Current Assets
11
16
9
Cash, Cash Equivalents & STI
7
12
7
Accounts Receivable, Net
1
1
1
Inventories
2
1
1
Total Current Liabilities
7
8
7
Payables & Accruals
1
3
2
ST Debt
4
4
4
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-121.03%
-178.34%
-48.16%
Free Cash Flow
10.31%
2.05%
7.45%
Net Income, GAAP
7.88%
4.06%
25.95%
Sales/Revenue/Turnover
23%
-8.96%
-28.52%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
1
2
3
3
9
2022
1
1
1
2
6
2023
1
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
-9.63
-4.69
-7.24
- -
-29.66
2022
-9.73
-6.42
-4.91
- -
-24.28
2023
-2.28
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
Similar Companies
Stratec SE (STSEY)
Burning Rock Biotech Limited (BNR)
Thermo Fisher Scientific Inc. (TMO)
Diaceutics PLC (DIUXF)
Precision System Science Co., Ltd. (7707.T)
Taihe Group, Inc. (TIHE)
Business
HTG Molecular Diagnostics, Inc. was formerly a life sciences enterprise dedicated to advancing precision medicine through innovative molecular profiling solutions. The company previously provided specialized instruments, consumables, and software designed to streamline sample processing and analyze diverse molecular targets. Its offerings included a range of molecular profiling panels such as the HTG Transcriptome Panel, HTG EdgeSeq precision immuno-oncology panel, and the HTG EdgeSeq Oncology Biomarker Panel, among others. These products were distributed directly in the United States and Europe, and through partners internationally, serving biopharmaceutical firms, academic research institutions, and specialized testing laboratories. Originally incorporated as HTG, Inc. in 1997 in Tucson, Arizona, the company adopted its current name in March 2011. HTG Molecular Diagnostics, Inc. initiated voluntary reorganization proceedings under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware on June 5, 2023. Subsequently, on May 21, 2025, the Chapter 11 case was converted to a Chapter 7 liquidation.